Effect of Changes in Dialysate Bicarbonate on Serum Calcification Propensity and Calciprotein Particles in Hemodialysis Patients - Trial NCT06084858
Access comprehensive clinical trial information for NCT06084858 through Pure Global AI's free database. This Phase 2 trial is sponsored by Prim. Priv. Doz. Dr. Daniel Cejka and is currently Not yet recruiting. The study focuses on End Stage Renal Disease. Target enrollment is 24 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Prim. Priv. Doz. Dr. Daniel Cejka
Elisabethinen Hospital
Timeline & Enrollment
Phase 2
Dec 01, 2023
Dec 01, 2024
Primary Outcome
T50-Laboratory Test for measuring calcification
Summary
This is a single-center, prospective, proof-of-priciple, pilot study in 24 end-stage renal
 disease patients on chronic hemodiaysis.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06084858
Non-Device Trial